Superworth

vTv Therapeutics profit margin VTVT

Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.

Net margin, 12 months
−12.9%
Operating margin, 12 months
−25.1%
Peer median
11.6%

Over the twelve months to Jun 30, 2026, vTv Therapeutics kept −12.9% of its revenue as net profit, with an operating margin of −25.1%.

Five years earlier its net margin was −71.0%.

The median for 10 large drugmakers of a similar size is 11.6%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet margin
FY2025n/a
FY2024n/a
FY2023n/a
FY2022n/a
FY2021n/a
FY2020n/a
FY2019n/a
FY2018−63.6%
FY2017n/a
FY2016n/a
FY2015n/a
FY2014n/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−12.9%n/a−25.1%
Q1 FY266.1%n/a−8.3%
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest vTv Therapeutics' size, closest first, today.

CompanyProfit margin
VTVTvTv Therapeutics−12.9%
LFVNLifevantage2.8%
SPROSpero Therapeutics15.7%
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products3.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
COLLCollegium Pharmaceutical5.9%
Peer median11.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on vTv Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.